Tag: Pembrolizumab

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Pembrolizumab

PDS Biotech reaffirms guidance for clinical trial | Company Announcement - Investegate

Added to Collection on: 2025-02-05 15:30:07

Tags for this article:

Cancer immunotherapy
Antineoplastic drugs
Otorhinolaryngology
Pembrolizumab
Human papillomavirus infection
Head and neck cancer
Checkpoint inhibitor
Targeted therapy
pds biotechnology corporation

Click the tags to see associated articles and topics

View Article Details
Intratumoral Injection of mRNA-2752 and Pembrolizumab in High-Risk DCIS

Added to Collection on: 2025-02-12 18:07:13

Tags for this article:

Antineoplastic drugs
Cancer immunotherapy
Pembrolizumab
Breast cancer
Biotechnology

Click the tags to see associated articles and topics

View Article Details
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - February 25, 2025

Added to Collection on: 2025-02-25 12:42:02

Tags for this article:

Antineoplastic drugs
Research and development in the United States
Lung cancer
Pfizer
Antibody-drug conjugate
Non-small-cell lung cancer
Pembrolizumab
Summit Therapeutics PLC

Click the tags to see associated articles and topics

View Article Details
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer

Added to Collection on: 2025-03-04 19:50:09

Tags for this article:

Orphan drugs
BeiGene
Esophageal cancer
Tislelizumab
ESCC
Squamous-cell carcinoma
Pembrolizumab
Atezolizumab

Click the tags to see associated articles and topics

View Article Details
Purple Biotech Granted New U.S. Patent for NT219 in - GlobeNewswire

Added to Collection on: 2025-03-05 12:38:01

Tags for this article:

Cancer immunotherapy
Immune system
Biotechnology
Oncogenes
Antineoplastic drugs
Cetuximab
Epidermal growth factor receptor
Head and neck cancer
Pembrolizumab
Panitumumab
Checkpoint inhibitor
Tumor microenvironment
REHOVOT
Purple Biotech Ltd.
Israel

Click the tags to see associated articles and topics

View Article Details
FDA Approves BeiGene's Tevimbra for Unresectable or Metastatic Esophageal Squamous ...

Added to Collection on: 2025-03-05 08:01:35

Tags for this article:

Orphan drugs
Cancer
Antineoplastic drugs
Monoclonal antibodies
Esophageal cancer
Gastrointestinal cancer
Squamous-cell carcinoma
BeiGene
ESCC
Adenocarcinoma
Tislelizumab
Pembrolizumab

Click the tags to see associated articles and topics

View Article Details
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% During the Study ...

Added to Collection on: 2025-03-06 23:48:38

Tags for this article:

Orphan drugs
Merkel-cell carcinoma
Cancer immunotherapy
Antineoplastic drugs
Avelumab
Pembrolizumab
Cancer
Merkel cell polyomavirus
Merus NV
Kymera Therapeutics
Phio Pharmaceuticals
Philogen

Click the tags to see associated articles and topics

View Article Details
PDS Biotech Launches First Phase 3 Trial for HPV16 Head and Neck Cancer Treatment

Added to Collection on: 2025-03-07 19:53:45

Tags for this article:

Cancer immunotherapy
Papillomavirus
Otorhinolaryngology
Antineoplastic drugs
Orphan drugs
Pembrolizumab
Human papillomavirus infection
Head and neck cancer
Checkpoint inhibitor
HPV-positive oropharyngeal cancer
Katharine Price
pds biotechnology corporation

Click the tags to see associated articles and topics

View Article Details
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial

Added to Collection on: 2025-03-15 05:23:27

Tags for this article:

Antineoplastic drugs
Biotechnology
Immunology
Cancer immunotherapy
Antibody-drug conjugate
Genetic engineering
Pembrolizumab

Click the tags to see associated articles and topics

View Article Details
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs ...

Added to Collection on: 2025-03-20 17:51:01

Tags for this article:

Antineoplastic drugs
Cancer
Melanoma
Cancer immunotherapy
Cancer vaccine
Immunotherapy
Orphan drugs
Immunology
Pembrolizumab
Ipilimumab
ResearchAndMarkets.com

Click the tags to see associated articles and topics

View Article Details